Fluconazole
Phase 3Completed 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Vulvovaginal Candidiasis
Conditions
Vulvovaginal Candidiasis
Trial Timeline
Mar 5, 2013 โ Nov 22, 2013
NCT ID
NCT01806623About Fluconazole
Fluconazole is a phase 3 stage product being developed by Pfizer for Vulvovaginal Candidiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01806623. Target conditions include Vulvovaginal Candidiasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002077 | Pre-clinical | Completed |
| NCT00002306 | Pre-clinical | Completed |
| NCT00000627 | Pre-clinical | Completed |
| NCT00002040 | Pre-clinical | Completed |
| NCT00002010 | Pre-clinical | Completed |
| NCT00002325 | Pre-clinical | Completed |
| NCT00000744 | Pre-clinical | Completed |
| NCT00002339 | Phase 3 | Completed |
| NCT00002038 | Pre-clinical | Completed |
| NCT00002294 | Pre-clinical | Completed |
| NCT00002076 | Pre-clinical | Completed |
| NCT01806623 | Phase 3 | Completed |
| NCT01680458 | Pre-clinical | Completed |
| NCT00645242 | Phase 3 | Completed |
Competing Products
10 competing products in Vulvovaginal Candidiasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR8008 + Fluconazole | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| SHR8008 capsule + Fluconazole capsule | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Estradiol 10 MCG Vaginal Tablet [VAGIFEM] + Promestriene Vaginal | Novo Nordisk | Phase 3 | 76 |
| Clotrimazole vaginal tablet + Fluconazole | Bayer | Approved | 82 |
| SCY-078 + Fluconazole | Scynexis | Phase 2 | 44 |
| Ibrexafungerp | Scynexis | Phase 3 | 69 |
| Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tablet | Scynexis | Phase 3 | 69 |
| Ibrexafungerp | Scynexis | Phase 1 | 25 |
| Estradiol + Placebo | TherapeuticsMD | Phase 3 | 69 |
| Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB) | Matinas Biopharma | Phase 2 | 44 |